Actinium Pharmaceuticals IncNYSE American:ATNM
- LAST PRICE9.8500
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots9.6100/ 3
- Ask / Lots10.0800/ 1
- Open / Previous Close0.0000 / 9.8500
- Day Range---
- 52 Week Range
- Volume204
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ATNM |
|---|---|---|
| 09:32 ET | 6670 | 9.57 |
| 09:34 ET | 1200 | 9.75 |
| 09:36 ET | 1000 | 9.9587 |
| 09:39 ET | 100 | 9.88 |
| 09:43 ET | 1400 | 9.9399 |
| 09:45 ET | 650 | 9.7845 |
| 09:48 ET | 300 | 9.79 |
| 09:52 ET | 155 | 9.7507 |
| 09:54 ET | 1330 | 9.76 |
| 09:56 ET | 200 | 9.83 |
| 09:57 ET | 842 | 9.78 |
| 10:06 ET | 420 | 9.8 |
| 10:08 ET | 710 | 9.66 |
| 10:12 ET | 3061 | 9.68 |
| 10:15 ET | 400 | 9.655 |
| 10:17 ET | 200 | 9.6525 |
| 10:19 ET | 7732 | 9.695 |
| 10:24 ET | 2520 | 9.7107 |
| 10:26 ET | 512 | 9.8037 |
| 10:30 ET | 100 | 9.8 |
| 10:32 ET | 409 | 9.777 |
| 10:33 ET | 100 | 9.798 |
| 10:35 ET | 500 | 9.7673 |
| 10:37 ET | 1850 | 9.8148 |
| 10:39 ET | 110 | 9.845 |
| 10:42 ET | 1400 | 9.84 |
| 10:44 ET | 1300 | 9.74 |
| 10:46 ET | 1700 | 9.75 |
| 10:48 ET | 200 | 9.715 |
| 10:50 ET | 500 | 9.61 |
| 10:53 ET | 1100 | 9.63 |
| 10:57 ET | 1520 | 9.6525 |
| 11:00 ET | 200 | 9.63 |
| 11:06 ET | 432 | 9.7 |
| 11:08 ET | 1600 | 9.7 |
| 11:09 ET | 1700 | 9.68 |
| 11:13 ET | 3625 | 9.71 |
| 11:18 ET | 400 | 9.71 |
| 11:20 ET | 216 | 9.73 |
| 11:22 ET | 1100 | 9.73 |
| 11:24 ET | 1200 | 9.77 |
| 11:26 ET | 300 | 9.73 |
| 11:27 ET | 300 | 9.75 |
| 11:29 ET | 407 | 9.755 |
| 11:31 ET | 206 | 9.7565 |
| 11:42 ET | 400 | 9.78 |
| 11:49 ET | 9740 | 9.9 |
| 11:51 ET | 1000 | 9.895 |
| 11:54 ET | 3415 | 9.9138 |
| 11:56 ET | 400 | 9.9101 |
| 11:58 ET | 100 | 9.94 |
| 12:02 ET | 100 | 9.925 |
| 12:03 ET | 2700 | 9.93 |
| 12:05 ET | 166 | 9.9194 |
| 12:07 ET | 100 | 9.92 |
| 12:09 ET | 3350 | 9.93 |
| 12:12 ET | 1000 | 9.91 |
| 12:16 ET | 1720 | 9.89 |
| 12:18 ET | 1900 | 9.91 |
| 12:20 ET | 100 | 9.915 |
| 12:25 ET | 1049 | 9.9 |
| 12:30 ET | 381 | 9.89 |
| 12:34 ET | 1350 | 9.895 |
| 12:38 ET | 300 | 9.9 |
| 12:41 ET | 100 | 9.9 |
| 12:43 ET | 200 | 9.9004 |
| 12:56 ET | 380 | 9.895 |
| 12:57 ET | 301 | 9.87 |
| 12:59 ET | 600 | 9.89 |
| 01:03 ET | 1000 | 9.8925 |
| 01:10 ET | 1290 | 9.88 |
| 01:17 ET | 100 | 9.87 |
| 01:21 ET | 400 | 9.8647 |
| 01:24 ET | 1956 | 9.86 |
| 01:26 ET | 500 | 9.87 |
| 01:30 ET | 253 | 9.85 |
| 01:33 ET | 100 | 9.87 |
| 01:35 ET | 100 | 9.87 |
| 01:37 ET | 100 | 9.87 |
| 01:39 ET | 100 | 9.9 |
| 01:48 ET | 400 | 9.88 |
| 01:50 ET | 5650 | 9.82 |
| 01:51 ET | 399 | 9.8245 |
| 01:55 ET | 331 | 9.84 |
| 02:02 ET | 1167 | 9.84 |
| 02:08 ET | 783 | 9.82 |
| 02:11 ET | 200 | 9.81 |
| 02:15 ET | 612 | 9.8 |
| 02:18 ET | 401 | 9.81 |
| 02:22 ET | 100 | 9.78 |
| 02:29 ET | 100 | 9.81 |
| 02:33 ET | 100 | 9.81 |
| 02:36 ET | 3248 | 9.815 |
| 02:38 ET | 100 | 9.84 |
| 02:40 ET | 114 | 9.815 |
| 02:42 ET | 100 | 9.84 |
| 02:44 ET | 2000 | 9.8399 |
| 02:45 ET | 9893 | 9.86 |
| 02:49 ET | 745 | 9.81 |
| 02:51 ET | 100 | 9.86 |
| 02:54 ET | 468 | 9.85 |
| 02:56 ET | 100 | 9.85 |
| 02:58 ET | 110 | 9.8483 |
| 03:00 ET | 7701 | 9.83 |
| 03:07 ET | 100 | 9.81 |
| 03:09 ET | 3066 | 9.825 |
| 03:12 ET | 1550 | 9.83 |
| 03:14 ET | 1466 | 9.81 |
| 03:16 ET | 200 | 9.82 |
| 03:18 ET | 500 | 9.8 |
| 03:20 ET | 300 | 9.78 |
| 03:21 ET | 100 | 9.79 |
| 03:23 ET | 100 | 9.78 |
| 03:27 ET | 1954 | 9.7767 |
| 03:30 ET | 275 | 9.77 |
| 03:32 ET | 400 | 9.8 |
| 03:34 ET | 400 | 9.825 |
| 03:36 ET | 209 | 9.8 |
| 03:38 ET | 300 | 9.83 |
| 03:41 ET | 1685 | 9.82 |
| 03:43 ET | 400 | 9.805 |
| 03:45 ET | 5028 | 9.78 |
| 03:48 ET | 450 | 9.8 |
| 03:50 ET | 2921 | 9.825 |
| 03:52 ET | 2850 | 9.76 |
| 03:54 ET | 100 | 9.785 |
| 03:56 ET | 7641 | 9.83 |
| 03:57 ET | 6333 | 9.77 |
| 03:59 ET | 23616 | 9.85 |
May 15, 2024
Actinium to Host KOL Webinar to Discuss Iomab-ACT Commercial CAR T-Cell Therapy Trial Design, Objectives and Potential Market Opportunity, from 8:30AM ET on Wednesday May 15, 2024 by Dow Jones
8:30AM ET on Wednesday May 15, 2024 by Dow Jones
May 14, 2024
Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phase 3 SIERRA Trial, from 6:38PM ET on Tuesday May 14, 2024 by Dow Jones
6:38PM ET on Tuesday May 14, 2024 by Dow JonesDJ Actinium Pharmaceuticals Initiated at Overweight by Stephens & Co., from 6:05AM ET on Tuesday May 14, 2024 by Dow Jones
6:05AM ET on Tuesday May 14, 2024 by Dow Jones
May 13, 2024
Actinium Announces Multiple Abstracts Highlighting its Antibody Radiation Conjugates Iomab-B and Actimab-A and Novel Linker Technology for Solid Tumors Accepted for Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting, from 8:30AM ET on Monday May 13, 2024 by Dow Jones
8:30AM ET on Monday May 13, 2024 by Dow Jones
May 7, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Actinium Pharmaceuticals Inc | 293.4M | -5.7x | --- |
Inozyme Pharma Inc | 292.6M | -3.5x | --- |
Invivyd Inc | 292.1M | -1.3x | --- |
Black Diamond Therapeutics Inc | 294.8M | -3.1x | --- |
Opthea Ltd | 297.2M | -1.4x | --- |
Verastem Inc | 307.0M | -2.8x | --- |
Company Information
Actinium Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing targeted radiotherapies to improve survival for people who have failed existing oncology therapies. The Company’s advanced pipeline candidates include Iomab-B (pre-BLA & MAA (EU)) and Actimab-A. Iomab-B is an induction and conditioning agent prior to bone marrow transplant. Actimab-A is a therapeutic agent, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. The Company focuses on advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. The Company holds patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron. Actinium-225 is a potent alpha-particle emitter that has high linear energy transfer capable of killing targeted cancer cells via double-strand breaks in DNA.
Contact Information
- Headquarters
- 100 Park Ave., 23Rd FloorNEW YORK, NY, United States 10017
- Phone
- 646-677-3870
- Fax
- 845-818-3588
Executives
- Chairman of the Board, Chief Executive Officer
- Sandesh Seth
- Chief Financial Officer
- Steve O'Loughlin
- Chief Business Officer
- Lynn Bodarky
- Independent Director
- Jeffrey Chell
- Lead Independent Director
- C. David Nicholson
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $293.4M |
|---|---|
Revenue (TTM) | $81.0K |
Shares Outstanding | 29.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.17 |
EPS | $-1.72 |
Book Value | $1.32 |
P/E Ratio | -5.7x |
Price/Sales (TTM) | 3,621.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -61,645.68% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
